In vitro evaluation of c7E3-Fab (ReoPro(TM)) eluting polymer-coated coronary stents

Cardiovascular Research

Volumn 46, Issue 3, 2000, Pages 585-594

  Baron, Julia H ^a   Gershlick, Anthony H ^a   Hogrefe, Kai ^a   Armstrong, Johanna ^b   Holt, Cathy M ^b   Aggarwal, Rajesh K ^a   Azrin, Michael ^c   Ezekowitz, Michael ^d   De Bono, David P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Monoclonal antibodies; Platelets; Restenosis; Stents; Thrombosis embolism

Indexed keywords

ABCIXIMAB;

ADSORPTION; ANTIGEN BINDING; ARTICLE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RESTENOSIS; SAPHENOUS VEIN; TEMPERATURE; THROMBOSIS;

ABSORPTION; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; CORONARY THROMBOSIS; EVALUATION STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STENTS;

EID: 0034037459     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00042-0     Document Type: Article

References (48)

1. Eekhout E., Wijns W., Meier B., Goy J.-J. Indications for coronary stent placement: The European view. Eur Heart J. 20:1999;1014-1019.
2. Hasdai D., Garrat K.N., Holmes D.R. Jr., Berger P.B., Schwartz R.S., Bell M.R. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol. 28:1996;361-367.
3. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet. 349:1997;1429-1435.
4. Platelet glycoprotein IIb/IIIa blockade and low-dose heparin during percutaneous coronary revascularisation. New Engl J Med. 336:1997;1689-1696.
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
6. Long term protection from myocardial ischaemic events in a randomised trial of brief integrin beta 3 blockade with percutaneous coronary intervention. J Am Med Assoc. 278:1997;479-484.
7. Lincoff A.M., Moliterno D.J., Ellis S.G., et al. 6-month angiographic outcome with abciximab and stents: The EPISTENT angiographic substudy. Circulation. 98:1998;I768. abstract.
8. Aggarwal R.K., Ireland D.C., Azrin M.A., Ezekowitz M.D., De Bono D., Gershlick A.H. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation. 94:1996;3311-3317.
9. Lincoff A.M., Topol E.J., Ellis S.G. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation. 90:1994;2070-2084.
10. Serruys P.W., van Hout B., Bonnier H., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 352:1998;673-681.
11. De Scheerder I., Wang K., Wilczek K., et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation. 95:1997;1549-1553.
12. Gao R., Shi R., Qiao S., et al. A novel polymeric local heparin delivery stent: Initial experimental study. J Am Coll Cardiol. 27:(suppl.):1996;84A. abstract.
13. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
14. Clowes A.W., Clowes M.M. Kinetics of cellular proliferation after arterial injury. II Inhibition of smooth muscle growth by heparin. Lab Invest. 52:1985;611-616.
15. Chronos N.A.F., Robinson K.A., Kelly A.B., et al. Neointima formation in stented baboon carotid arteries is reduced by bonded heparin: Correlation with decreased thrombogenicity. J Am Coll Cardiol. 27:1996;85A. abstract.
16. Brack M.J., Ray S., Chauhan A., et al. The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. J Am Coll Cardiol. 26:1995;947-954.
17. Schmidmaier G., Stemberger A., Alt E., et al. Non-linear time release characteristics of a biodegradable polyactic acid stent coating releasing PEG-hirudin and a PGI2 analog. Eur Heart J. 18:1997;571. abstract.
18. Azrin M.A., Ling F.S., Chen Q., et al. Preparation, characterisation, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. Circ Res. 75:1994;268-277.
19. Fraker P.J., Speck J.C. Protein and cell membrane iodinations with a sparingly soluble 1,3,4,6-tetrachloro-3a-6a-diphenylglycouril. Biochem Biophys Res Comm. 80:1978;849-857.
20. World Medical Association Declaration of Helsinki. Cardiovasc Res. 35:1997;2-3.
21. Fraker P.J., Speck J.C. Protein and cell membrane iodinations with a sparingly soluble 1,3,4,6-tetrachloro-3a-6a-diphenylglycouril. Biochem Biophys Res Comm. 80:1978;857.
22. Mascelli M.A., Worley S., Veriabo N.J., et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti GP IIb/IIIa therapy. Circulation. 96:1997;3860-3866.
23. Armstrong J., Holt C.M., Stratford P., Cumberland D.C. Phosphorylcholine stent coating as a method of local drug delivery: Preliminary data from an ex vivo model. Heart. 77:1997;47. abstract.
24. Galea J., Armstrong J., Francis S.E., Cooper G., Crossman D.C., Holt C.M. Alterations in c-fos expression, cell proliferation and apoptosis in pressure distended human saphenous vein. Cardiovasc Res. 44:1999;436-448.
25. Jordan R.E., Wagner C.L., Mascelli M.A., et al. Preclinical development of c7E3-Fab: A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3-Fab in humans. Horton M.A. Adhesion receptors as therapeutic targets. 1995;281-305 CRC Press, London.
26. Colombo A., Hall P., Nakamura S., et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 91:1995;1676-1688.
27. LaBlache J.-M., Mcfadden E.P., Bonnet J.-L., et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to coronary stent management. Eur Heart J. 17:1996;1373-1380.
28. Karrillon C.J., Morice M.C., Benveniste E., et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation with antiplatelet therapy. 30 day clinical outcome of the French Multicenter registry. Circulation. 94:1996;1519-1527.
29. Katrati A., Elezi S., Dirschinger J., Hadamitzky M., Neumann F.-J., Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol. 83:1999;1617-1622.
30. Elezi S., Kastrati A., Pache J., et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 32:1998;1866-1873.
31. Akiyama T., Moussa I., Reimers B., et al. Angiographic and clinical outcome following coronary stenting of small vessels: A comparison with stenting of large vessels. J Am Coll Cardiol. 32:1998;1610-1618.
32. Costa M.A., Sabate M., Wim J., et al. Late coronary occlusion after brachytherapy. Circulation. 100:1999;789-792.
33. Camenzind E., Reys A., Lighart J., et al. Local intracoronary delivery of heparin and of a somatostatin analogue (Octreotide) following angioplasty in man: Evaluation of efficiency of delivery by radio-isotope technique. J Am Coll Cardiol. 25:1995;285A. abstract.
34. Fischell T.A. Polymer coatings for stents. Can we judge a stent by its cover? Circulation. 94:1996;1494-1495.
35. Ven der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 94:1996;1690-1697.
36. Kornowski R., Hong M.K., Ragheb A.O., Bramwell O., Leon M.B. Slow-release Taxol coated GRII™ stents reduce neointima formation in a porcine coronary in-stent restenosis model. Circulation. 96:1997;I341. abstract.
37. Lansky A.J., Curran M.J., Hanzel G.S., Fearnot N., Kannam J.P., Popma J.J. The impact of stent size selection on clinical outcome after use of the Gianturco Roubin II stent. Results from the randomised clinical trial. Circulation. 98:1998;I160-I161. abstract.
38. 2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 66:1985;1456-1459.
39. 3 integrin: A possible explanation for prevention of restenosis. Circulation. 98:1998;I809. abstract.
40. 3 integrins. Circulation. 98:(11):1998;1085-1091.
41. 3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I. Proc Natl Acad Sci USA. 93:1996;2482-2487.
42. 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 95:1995;713-724.
43. Clowes A.W., Schwartz S.M. Significance of quiescent smooth muscle cell migration in the injured rat carotid artery. Circ Res. 56:1985;139-145.
44. 3 and osteopontin expression during neointima formation. Cardiovasc Res. 36:1997;408-428.
45. Le Breton H., Plow E.F., Topol E.J. Role of platelets in restenosis after percutaneous coronary revascularisation. J Am Coll Cardiol. 28:1996;1643-1651.
46. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 101:1994;1757-1764.
47. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. Circulation. 100:1999;799-806.
48. Marijianowski M.M., Nakada M.T., Sundell B., et al. Abciximab reduces vascular lesion formation in non human primates. J Am Coll Cardiol. 33:1999;69. abstract.